Literature DB >> 12192244

Mediators of injury in lupus nephritis.

Jim C Oates1, Gary S Gilkeson.   

Abstract

Systemic lupus erythematosus (SLE) is a prototypic autoimmune disease characterized by the production of autoantibodies and the development of immune complex glomerulonephritis. Lupus nephritis (LN) remains a leading cause of morbidity and mortality in SLE. As a result, defining pathogenetic mediators in LN remains a major research effort. Progression to LN in SLE is dependent on the host breaking immune tolerance and forming autoantibodies that deposit in the kidney. A variety of predisposing factors in the host must then be present for this event to result in renal pathology. In this article, the authors review recent reports that advance our understanding of LN disease mediators, from autoantibody production and immune complex deposition to end stage fibrosis.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12192244     DOI: 10.1097/00002281-200209000-00003

Source DB:  PubMed          Journal:  Curr Opin Rheumatol        ISSN: 1040-8711            Impact factor:   5.006


  13 in total

1.  MicroRNA-let-7a expression is increased in the mesangial cells of NZB/W mice and increases IL-6 production in vitro.

Authors:  Cristen B Chafin; Nicole L Regna; Rujuan Dai; David L Caudell; Christopher M Reilly
Journal:  Autoimmunity       Date:  2013-09       Impact factor: 2.815

2.  Cellular and urinary microRNA alterations in NZB/W mice with hydroxychloroquine or prednisone treatment.

Authors:  Cristen B Chafin; Nicole L Regna; Sarah E Hammond; Christopher M Reilly
Journal:  Int Immunopharmacol       Date:  2013-10-09       Impact factor: 4.932

3.  Activation-induced deaminase-deficient MRL/lpr mice secrete high levels of protective antibodies against lupus nephritis.

Authors:  Chuancang Jiang; Ming-Lang Zhao; Richard M Scearce; Marilyn Diaz
Journal:  Arthritis Rheum       Date:  2011-04

4.  Regulatory effect of melatonin on cytokine disturbances in the pristane-induced lupus mice.

Authors:  Ling-Ling Zhou; Wei Wei; Jun-Feng Si; Dong-Ping Yuan
Journal:  Mediators Inflamm       Date:  2010-07-20       Impact factor: 4.711

5.  Increased survival and reduced renal injury in MRL/lpr mice treated with a novel sphingosine-1-phosphate receptor agonist.

Authors:  Scott E Wenderfer; Stanislaw M Stepkowski; Michael C Braun
Journal:  Kidney Int       Date:  2008-09-03       Impact factor: 10.612

6.  The mouse and human Fli1 genes are similarly regulated by Ets factors in T cells.

Authors:  J L Svenson; K Chike-Harris; M Y Amria; T K Nowling
Journal:  Genes Immun       Date:  2009-10-15       Impact factor: 2.676

7.  Interleukin-6 deficiency corrects nephritis, lymphocyte abnormalities, and secondary Sjögren's syndrome features in lupus-prone Sle1.Yaa mice.

Authors:  Jacen S Maier-Moore; Christopher G Horton; Shirley A Mathews; Anthony W Confer; Christina Lawrence; Zijian Pan; K Mark Coggeshall; A Darise Farris
Journal:  Arthritis Rheumatol       Date:  2014-09       Impact factor: 10.995

8.  Deficiency of activating Fcγ-receptors reduces hepatic clearance and deposition of IC and increases CIC levels in mercury-induced autoimmunity.

Authors:  Klara Martinsson; Thomas Skogh; Seyed Ali Mousavi; Trond Berg; Jan-Ingvar Jönsson; Per Hultman
Journal:  PLoS One       Date:  2010-10-15       Impact factor: 3.240

9.  A GA microsatellite in the Fli1 promoter modulates gene expression and is associated with systemic lupus erythematosus patients without nephritis.

Authors:  Erin E Morris; May Y Amria; Emily Kistner-Griffin; John L Svenson; Diane L Kamen; Gary S Gilkeson; Tamara K Nowling
Journal:  Arthritis Res Ther       Date:  2010-11-18       Impact factor: 5.156

10.  The ambiguity in immunology.

Authors:  Vincenzo Barnaba; Marino Paroli; Silvia Piconese
Journal:  Front Immunol       Date:  2012-02-22       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.